Title SITC’s Guide to Managing Immunotherapy Toxicity
Subtitle
Author Marc S. Ernstoff, Igor Puzanov, Caroline Robert, Adi Diab, Peter Hersey
ISBN 9780826172143
List price USD 50.00
Price outside India Available on Request
Original price
Binding Paperback
No of pages 274
Book size 210 X 222 mm
Publishing year 2019
Original publisher Demos Medical Publishing
Published in India by .
Exclusive distributors .
Sales territory Bangladesh, India, Pakistan, Sri Lanka
Status New Arrival
About the book Send Enquiry
  
 

Description:

The Society for Immunotherapy of Cancer’s handbook, SITC’s Guide to Managing Immunotherapy Toxicity, is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Separated into two parts, Part I contains chapter-based overviews of immune checkpoint inhibitors in the clinic, starting with anti-CTLA4 agents, anti-PD1/PD-L1 agents, and approved immunotherapeutic combinations. These chapters cover relevant mechanisms of action, indications, and toxicities seen while combating early, advanced, and metastatic stages in cancer patients. Part II is structured by common and uncommon toxicities that affect major organ sites throughout the body. It begins with a general summary of principles and management options followed by chapters focusing on specific toxicities such as rash and mucosal irritation, muscle and joint toxicity, diarrhea and colitis, pneumonitis, endocrine toxicities, neurological toxicities, cardiac toxicity, renal toxicity, hematologic toxicity, and ocular toxicities. Each chapter provides guidance on how to assess and treat the toxicity and how to support the patient through acute and chronic effects with detailed summary tables for quick reference. Part II concludes with chapters covering management of special patient populations, including patients with autoimmune disease and geriatric patients, treatment and management of fatigue, and a final chapter dedicated to cost effectiveness and the toll of financial toxicity on patients and caregivers.

With chapters written by world-recognized leaders in the immuno-oncology field, this text provides thorough coverage of the toxicity and management of adverse effects for immune checkpoint inhibitors. It is an indispensable resource for clinical oncologists, emergency physicians, hospitalists and other medical practitioners in both the hospital and community clinic settings, especially as the use of immune checkpoint inhibitors becomes a fixture in oncology care.

 

Key Features:

  • Outlines strategies for treating high-risk patients facing an acute or chronic side effect to immunotherapy
  • Provides numerous tables that condense and highlight pertinent information for quick reference
  • Describes the various clinical presentations and toxic reactions caused by immunotherapy
  • Purchase includes access to the eBook for use on most mobile devices or computer

 


Contents:

Contributors

Foreword Lisa H. Butterfield, PhD and Howard L. Kaufman, MD

Introduction

Share: SITC’s Guide to Managing Immunotherapy Toxicity

 

Part I: Immune Checkpoint Inhibitors in the Clinic

Chapter 1. Overview of Anti-CTLA-4 Agents: Ipilimumab and Tremilimumab (Daniel Hartman Johnson and  Jianjun Gao)

Chapter 2. Overview of PD-1 and PD-L1 Inhibitors (Nikolaos Andreatos, Shailender Bhatia, and Petros Grivas)

Chapter 3. Indications and Toxicities of Immune Checkpoint Inhibitor Combinations (Lavinia Spain, Michael A. Postow, James Larkin, and Jeffrey Weber)

 

Part II: Specific Immune Checkpoint Inhibitor Toxicities

Chapter 4. General Principles of Immune-Related Toxicities (Osama E. Rahma and Patrick A. Ott)

Chapter 5. Dermatological Toxicities: Rash, Mucosal Irritation, and Pruritus (Jennifer Wu and Mario E. Lacouture)

Chapter 6. Musculoskeletal and Rheumatologic Toxicities (Noha Abdel-Wahab, Clifton O. Bingham III, and  Maria Suarez-Almazor)

Chapter 7. Immune-Related Gastrointestinal Toxicities (Hamzah Abu-Sbeih, Daniel Hartman Johnson, and Yinghong Wang)

Chapter 8. Pneumotoxicity Associated with Immune Checkpoint Blockades (Vickie R. Shannon)

Chapter 9. Immune-Related Endocrinopathies Associated with Immune Checkpoint Inhibitors (Rajeev Sharma, Ha Nguyen, and Ramona Dadu)

Chapter 10. Neurologic Adverse Events and Neurologic Complications (Haroon Ahmad, Jasmin Jo, Elizabeth Gaughan, and Camilo Fadul)

Chapter 11. Cardiovascular Toxicities Related to Immune Checkpoint Inhibitors (Pankit Vachhani, Igor Puzanov, and Javid J. Moslehi)

Chapter 12. Renal Toxicities Associated with Immune Checkpoint Inhibitors (Ala Abudayyeh, Maen Abdelrahim, and Laurence Albiges)

Chapter 13. Hematologic Toxicities of Apparent Immune-Related Origins (George L. Chen, Caroline Robert, and Alexander M. Lesokhin)

Chapter 14. Ocular Toxicities Caused by Immune Dysregulation (Liliya Golas and Dimitra Skondra)

Chapter 15. Safety and Regulation of Immune Checkpoint Inhibitors in Special Patient Populations (Douglas B. Johnson, Ryan Sullivan, and Paolo A. Ascierto )

Chapter 16. Cancer-Related Fatigue in Patients of Immune Checkpoint Inhibitor Therapy (Eric D. Hansen, Michelle Walter, and Amy A. Case)

Chapter 17. Cost Effectiveness and Financial Toxicity in New Cancer Therapies (Christine Kohn, Natalia Shcherbakova, and Alberto J. Montero)

Index


About the Editors:

Marc S. Ernstoff, MD
Professor, Department of Medicine, Katherine Anne Gioia Chair, Senior Vice President for Clinical Investigation, Roswell Park Comprehensive Cancer Center; Professor of Medicine, Chief, Hematology/Oncology, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, State University at Buffalo, Buffalo, New York.

Igor Puzanov, MD, MSCI, FACP
Professor of Medicine, Director, Early Phase Clinical Trials, Program Chief Melanoma Section, Roswell Park Cancer Institute, Buffalo, New York

Caroline Robert, MD, PhD
Professor of Dermatology, Chief of Dermatology Service, Co-Direction of Melanoma Research Team, Institute Gustave Roussy, Paris, France.

Adi Diab, MD
Assistant Professor, Department of Melanoma Medical Oncology Division of Cancer Medicine, The University of Texas MD Anderson, Cancer Center Houston, Texas.

Peter Hersey, MD, PhD
Honorary Professor in Immuno-Oncology, Centenary Institute, University of Sydney, Sydney, Australia.

 

Target Audience:

It is an indispensable resource for clinical oncologists, emergency physicians, hospitalists and other medical practitioners in both the hospital and community clinic settings, especially as the use of immune checkpoint inhibitors becomes a fixture in oncology care.

 
Special prices are applicable to the authorised sales territory only.
Prices are subject to change without prior notice.